Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
125
datasets available to search
ShareScore release 0.9.0
Dataset results
125 results for “Relapsing-remitting multiple sclerosis”
Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT03594487. IPD Sharing: YES. Countries: 1. Publications: 10.
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00879658. IPD Sharing: UNDECIDED. Countries: 12. Publications: 2.
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00355134. IPD Sharing: Not stated. Countries: 8. Publications: 6.
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01006265. IPD Sharing: Not stated. Countries: 23. Publications: 2.
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01064401. IPD Sharing: Not stated. Countries: 28. Publications: 7.
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
ClinicalTrials.gov study NCT01226745. IPD Sharing: Not stated. Countries: 11. Publications: 0.
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
ClinicalTrials.gov study NCT00211887. IPD Sharing: Not stated. Countries: 2. Publications: 12.
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
ClinicalTrials.gov study NCT02342704. IPD Sharing: Not stated. Countries: 9. Publications: 1.
A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the Reb
ClinicalTrials.gov study NCT01791244. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01416155. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Mult
ClinicalTrials.gov study NCT00870740. IPD Sharing: Not stated. Countries: 8. Publications: 2.
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
ClinicalTrials.gov study NCT02283853. IPD Sharing: YES. Countries: 18. Publications: 1.
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00050778. IPD Sharing: Not stated. Countries: 5. Publications: 12.
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00289978. IPD Sharing: Not stated. Countries: 19. Publications: 9.
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00420212. IPD Sharing: Not stated. Countries: 29. Publications: 11.
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
ClinicalTrials.gov study NCT00340834. IPD Sharing: Not stated. Countries: 18. Publications: 7.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01185821. IPD Sharing: Not stated. Countries: 12. Publications: 1.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01457924. IPD Sharing: Not stated. Countries: 11. Publications: 1.
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT04075266. IPD Sharing: YES. Countries: 3. Publications: 1.
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
ClinicalTrials.gov study NCT00605215. IPD Sharing: Not stated. Countries: 19. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.